Liu Guohui, Su Yao, He Yunlong, Hu Hanqing
Department of Radiation Oncology The Harbin Medical University Cancer Hospital Harbin Heilongjiang China.
Obstetrical Department The First Affiliated Hospital of Harbin Medical University Harbin Heilongjiang China.
Cancer Innov. 2025 May 22;4(3):e70010. doi: 10.1002/cai2.70010. eCollection 2025 Jun.
As immunotherapy rises to prominence in cancer treatment, the therapeutic approach to esophageal cancer is undergoing significant transformations. This review emphasizes the necessity and optimization pathways for adjuvant postoperative radiotherapy after neoadjuvant therapy in patients with esophageal cancer in the immunotherapy era. Initially, we review the advancements in neoadjuvant treatment strategies. Subsequently, we evaluate the role of postoperative radiotherapy and the latest advancements in radiotherapy target volume definition and dose optimization following neoadjuvant therapy, as well as the implications of tumor immunotherapy on postoperative radiotherapy strategies. In conclusion, in the new era of immunotherapy, postoperative radiotherapy following neoadjuvant therapy for esophageal cancer holds significant value. Optimization strategies should follow individualized treatment principles and comprehensively consider tumor biology, patient status, and treatment resources to achieve optimal therapeutic outcomes and quality of life, thereby driving continuous innovation in esophageal cancer treatment.
随着免疫疗法在癌症治疗中日益突出，食管癌的治疗方法正在经历重大变革。本综述强调了免疫治疗时代食管癌患者新辅助治疗后辅助性术后放疗的必要性和优化途径。首先，我们回顾新辅助治疗策略的进展。随后，我们评估术后放疗的作用以及新辅助治疗后放疗靶区定义和剂量优化的最新进展，以及肿瘤免疫治疗对术后放疗策略的影响。总之，在免疫治疗的新时代，食管癌新辅助治疗后的术后放疗具有重要价值。优化策略应遵循个体化治疗原则，综合考虑肿瘤生物学、患者状况和治疗资源，以实现最佳治疗效果和生活质量，从而推动食管癌治疗的持续创新。
